Yuda et al. report the development and evaluation of a novel selective MCL-1 inhibitor, ABBV-467. The compound is efficacious in preclinical models but increases in cardiac troponin are seen in a first-in-human study, suggesting potential cardiac toxicity of the drug.
- Junichiro Yuda
- Christine Will
- Andrew J. Souers
